Xeris Biopharma Holdings Inc Reports Q3 2024 Revenue of 54. ...
XERS Stock | USD 3.09 0.05 1.64% |
Slightly above 71 percent of all Xeris Pharmaceuticals' private investors are curious in acquiring. The analysis of overall sentiment of trading Xeris Pharmaceuticals stock suggests that a large number of investors are confidant at this time. Xeris Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Xeris Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Xeris |
Total Revenue Achieved a record 54.3 million, surpassing the analyst estimate of 51.43 million, driven by strong demand for Recorlev and Gvoke.Product R
Read at gurufocus.com
Xeris Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Xeris Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Xeris Pharmaceuticals Fundamental Analysis
We analyze Xeris Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xeris Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xeris Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Xeris Pharmaceuticals is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Xeris Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Xeris Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Xeris Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Xeris Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Xeris Pharmaceuticals Related Equities
CDTX | Cidara Therapeutics | 16.91 | ||||
MCRB | Seres Therapeutics | 5.48 | ||||
INZY | Inozyme Pharma | 4.46 | ||||
DAWN | Day One | 2.85 | ||||
PLX | Protalix Biotherapeutics | 1.81 | ||||
TERN | Terns Pharmaceuticals | 1.40 | ||||
IBRX | Immunitybio | 1.19 | ||||
MREO | Mereo BioPharma | 1.09 | ||||
ELEV | Elevation Oncology | 1.64 | ||||
HEPA | Hepion Pharmaceuticals | 4.35 | ||||
PDSB | PDS Biotechnology | 5.00 | ||||
HOOK | Hookipa Pharma | 6.52 | ||||
XFOR | X4 Pharmaceuticals | 8.11 |
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.